In type 2 diabetes, if good glycemic control is not maintained with oral antidiabetic agents (OADs), physicians often stop OADs and introduce twice-daily premixed insulins. In this 24-week, multicenter, open, parallel group study, 364 patients with type 2 diabetes and poor glycemic control using OADs were treated with once-daily insulin glargine (GLAR) with continued OADs (GLAR+OAD; glimepiride + metformin) or premixed 30% regular/70% human NPH insulin twice daily (70/30) alone. Insulin dosage was titrated to target fasting blood glucose (FBG) $\leq 100$ mg/dL ($\leq 5.6$ mmol/L) with GLAR+OAD and to both FBG $\leq 100$ mg/dL and pre-dinner BG $\leq 100$ mg/dL with 70/30, using a weekly forced-titration algorithm. To measure treatment satisfaction and change in treatment satisfaction, patients completed the Diabetes Treatment Satisfaction Questionnaire (DTSQs; status version) at baseline and endpoint and DTSQc (change version) at endpoint; 323 and 253 patients were included in the analysis of DTSQs and DTSQc scores, respectively. Maximum scores of 36.00 (DTSQs) and 18.00 (DTSQc) indicated optimal treatment satisfaction and improvement in treatment satisfaction. Mean HbA$_{1c}$ decrease was significantly greater ($-1.64$ vs $-1.31\%$; \(p=0.0003\)) and more patients reached HbA$_{1c} \leq 7.0\%$ without nocturnal hypoglycemia ($45.5$ vs $28.6\%$; \(p=0.0013\)) in the GLAR+OAD versus 70/30 group. At baseline, there was no difference in treatment satisfaction scores between the groups (GLAR+OAD: $26.91$ vs $70/30$: $26.26$; \(p=0.3603\)). At study end, scores increased in both groups but changes were significantly greater in the GLAR+OAD vs the 70/30 group ($+3.95$ vs $+2.32$; \(p=0.0022\)). For DTSQc, the treatment satisfaction score at study end was higher in GLAR+OAD- versus 70/30-treated patients (mean score $14.00$ vs $11.54$; \(p=0.0012\)). Initiating insulin therapy with the GLAR+OAD regimen is associated with a greater improvement in treatment satisfaction. 
satisfaction versus switching to twice-daily 70/30 alone.